Skip to main navigation
Skip to search
Skip to main content
UNT Health Home
Search content at UNT Health
Home
Research units
Profiles
Publications
Sponsored Projects
Core Facilities
Darunavir: A second-generation protease inhibitor
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Darunavir: A second-generation protease inhibitor'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Adverse Events
12%
AIDS/HIV
37%
Antiretroviral
12%
Antiretroviral Activity
6%
CD4+ T
6%
Cell Count
6%
Clinical Efficacy
12%
Combined Antiretroviral Therapy (cART)
6%
Cytochrome P450 (CYP450)
6%
Cytochrome P450 3A4 (CYP3A4)
6%
Darunavir
100%
Dosage Adjustment
6%
Drug Interactions
6%
Hepatic Dysfunction
6%
Infected Patients
6%
Isoenzymes
6%
MRNA Level
6%
Multidrug-resistant
6%
Multiple Proteases
6%
New Humanities
6%
Optimized Combination
6%
Pharmacokinetic Drug Interactions
6%
Pharmacology
6%
Place in Therapy
6%
Plasma Proteins
6%
Previously Treated
12%
Protease Inhibitors
100%
Renal Disease
6%
Ritonavir
6%
Safety Data
6%
Safety Profile
6%
Useful Components
6%
Virus RNA
6%
Virus Strains
6%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
12%
Bioavailability
6%
CYP3A4
6%
Cytochrome P450
6%
Darunavir
100%
Drug Interaction
6%
Drug-Drug Interaction
6%
HIV
31%
Human Immunodeficiency Virus Proteinase
6%
Isoenzyme
6%
Liver Dysfunction
6%
Mild Renal Impairment
6%
Moderate Renal Impairment
6%
Pharmacokinetics
6%
Plasma Protein
6%
Proteinase
6%
Proteinase Inhibitor
100%
Ritonavir
6%
Tablet
6%
Virus RNA
6%
Virus Strain
6%